Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00106808 · ClinicalTrials.gov registry record · Phase 3
Study of Muraglitazar Versus Pioglitazone in Type 2 Diabetes
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,440
- Enrollment target
NCT00106808: Completed Phase 3 study, sponsored by Bristol-Myers Squibb.
NCT00106808 is a Phase 3 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 1,440 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (87% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00106808, a Phase 3 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,440 participants
- Enrollment target
Study Summary
The purpose of this study is to compare Muraglitazar and Pioglitazone in patients with Type 2 Diabetes. Both the safety and blood sugar lowering effects of these treatments will be studied.
Interventions
- DRUG Pioglitazone
- DRUG Muraglitazar
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,440 participants |
| Start Date | 2005-08 |
| Est. Completion | 2006-08 |
| Phase | Phase 3 |
What the finished NCT00106808 record still lists
NCT00106808 is an interventional study that assigns participants to a tested intervention. Its 1,440 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (87% higher).
The record links to 0 conditions, and to 2 interventions - of which Pioglitazone is the first listed.
NCT00106808 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00106808 about?
NCT00106808 is a clinical study titled "Study of Muraglitazar Versus Pioglitazone in Type 2 Diabetes". The purpose of this study is to compare Muraglitazar and Pioglitazone in patients with Type 2 Diabetes. Both the safety and blood sugar lowering effects of these treatments will be studied.
What is the current status of trial NCT00106808?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,440 participants. The study started on 2005-08. Estimated completion is 2006-08.
What interventions are being tested in trial NCT00106808?
The interventions under investigation include: Pioglitazone (DRUG), Muraglitazar (DRUG).
Who is sponsoring clinical trial NCT00106808?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00106808's enrollment target sits among peer trials
1,440 167th of 2000 higher than 1,833 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04754022 · 1,440 participants · NA
Transfusion Requirements in Younger Patients Undergoing Cardiac Surgery
- NCT04989790 · 1,440 participants · NA
Clinical Effectiveness of the "PICU Up!" Multifaceted Early Mobility Intervention for Critically Ill Children
- NCT06122246 · 1,440 participants · NA
PRESSURE CHECK: Find Your Path to Better Health
- NCT06324318 · 1,440 participants · Phase 2
Parenting in 2 Worlds Multisite Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia